We excel in delivering end-to-end mammalian protein cGMP manufacturing services, bridging the gap between preclinical research and commercial-scale production. Our facilities operate under stringent cGMP guidelines, ensuring compliance with FDA, EMA, and ICH standards. From cell line development to final fill-finish, we prioritize scalability, product quality, and regulatory readiness. Explore our broader CDMO Solutions and specialized Mammalian Protein CDMO Services to advance your biologics pipeline.
Overview of Mammalian Protein cGMP Manufacturing
Mammalian protein production under cGMP is critical for biologics requiring complex post-translational modifications, such as monoclonal antibodies, recombinant enzymes, and fusion proteins. This process demands rigorous control over cell culture conditions, purification steps, and analytical validation to ensure batch consistency, purity, and safety. Key challenges include maintaining glycosylation fidelity, mitigating aggregation, and validating viral clearance. cGMP frameworks mandate traceability, documentation, and facility adherence to ISO cleanroom standards. Our approach integrates advanced technologies with risk-based strategies to accelerate timelines while meeting global regulatory expectations.
Our Capacities
Best-in-class Cell Line Engineering & Banking
We generate robust, high-titer CHO and HEK293 cell lines using advanced gene-editing tools, transposon integration systems, and high-throughput single-cell cloning. Extended genetic-stability studies (60+ generations) verify long-term performance, and all master cell banks (MCBs) are fully characterized and released in accordance with ICH Q5D and global regulatory expectations.
Scalable, High-Performance Upstream Manufacturing
Our bioreactor platforms, from benchtop to 2,000+ L, support both fed-batch and perfusion operations with seamless scale-up. Chemically defined media, metabolic modeling, and PAT-enabled control loops maximize cell health and productivity. Real-time in-process controls continuously monitor glucose, lactate, osmolality, and product accumulation to ensure batch consistency.
Industrial-Grade Downstream Purification & Viral Clearance
We deliver efficient, high-purity recovery using integrated multistep chromatography (Protein A, ion exchange, HIC) and validated viral clearance strategies including nanofiltration and low-pH hold. Adoption of continuous purification and single-use technologies reduces turnaround time and virtually eliminates cross-contamination risk, enabling agile GMP operations.
Robust Formulation Development & Aseptic Fill-Finish
Our formulation team designs highly stable liquid or lyophilized drug products by optimizing pH, excipients, osmolality, and stress-resistance profiles. cGMP fill-finish capabilities include vials, syringes, and cartridges under ISO Class 5 aseptic conditions, supported by rigorous container-closure integrity testing and full visual inspection.
Comprehensive Analytical, Release & Stability Testing
We provide a complete suite of cGMP assays including SEC-HPLC for aggregation, HCP ELISA, residual DNA qPCR, charge/size profiling, and potency evaluations via SPR and cell-based bioassays. Accelerated and long-term stability programs under ICH conditions (25°C/60% RH, 2–8°C, −20°C) confirm product shelf-life and support regulatory submissions.
Regulatory-Driven Documentation &QbD-Based Validation
Our specialists prepare IND-ready documentation, including process validation packages, comparability assessments, and end-to-end risk analyses. We support agency interactions and pre-approval inspections (PAIs) through a disciplined quality-by-design (QbD) framework, ensuring regulatory alignment and smooth clinical progression.
Our Major Equipment
- Single-Use Bioreactor Systems
Disposable bioreactors eliminate cleaning validation, reduce contamination risks, and enable rapid product changeover. Applications include seed train expansion and GMP manufacturing for early-phase programs.
- Continuous Manufacturing Platforms
Integrated perfusion bioreactors with alternating tangential flow (ATF) filtration and continuous chromatography (MCSGP) intensify productivity while maintaining cGMP compliance.
Frequently Asked Questions
Q1: What is the typical timeline for cGMP manufacturing of a mammalian protein?
Process development and initial GMP batches typically require 12–18 months. Timelines depend on product complexity, scale, and regulatory strategy. Accelerated pathways are available for fast-track-designated therapies.
Q2: Can you scale up from clinical to commercial production without process changes?
Yes. Our platform processes are designed for scalability, with qualified scale-down models to ensure equivalence. Comparability studies are conducted to address any minor adjustments.
Our products and services are for research use only.
